(Q37638287)

English

Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group

scientific article published on 13 February 2017

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group (English)

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

George Fountzilas

24

object named as

George Fountzilas

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Anna Batistatou

18

object named as

Anna Batistatou

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

author name string

Amanda Psyrri

1

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Konstantine T Kalogeras

2

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Ralph M Wirtz

3

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

George Kouvatseas

4

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Georgia Karayannopoulou

5

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Anna Goussia

6

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Flora Zagouri

7

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Elke Veltrup

8

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Eleni Timotheadou

9

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Helen Gogas

10

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Angelos Koutras

11

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Georgios Lazaridis

12

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Christos Christodoulou

13

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

George Pentheroudakis

14

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Panagiota Economopoulou

15

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Apostolos Laskarakis

16

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Petroula Arapantoni-Dadioti

17

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Maria Sotiropoulou

19

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Gerasimos Aravantinos

20

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Pavlos Papakostas

21

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Paris Kosmidis

22

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Dimitrios Pectasides

23

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

publication date

13 February 2017

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Journal of Translational Medicine

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

15

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

1

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

30

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Comparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304396

23 August 2017

Osteopontin splice variants are differential predictors of breast cancer treatment responses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304396

23 August 2017

Increased osteopontin protein expression may be correlated with poor prognosis in non-small-cell lung cancer: A meta analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304396

23 August 2017

The fibroblast Tiam1-osteopontin pathway modulates breast cancer invasion and metastasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304396

23 August 2017

Osteopontin Involves Cisplatin Resistance and Poor Prognosis in Oral Squamous Cell Carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304396

23 August 2017

The impact of osteopontin on prognosis and clinicopathology of colorectal cancer patients: a systematic meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304396

23 August 2017

Immune response gene expression in colorectal cancer carries distinct prognostic implications according to tissue, stage and site: a prospective retrospective translational study in the context of a hellenic cooperative oncology group randomised tri

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304396

23 August 2017

Prognostic value of osteopontin expression in breast cancer: A meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304396

23 August 2017

Osteopontin shapes immunosuppression in the metastatic niche

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304396

23 August 2017

Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304396

23 August 2017

Association of osteopontin and cyclooxygenase-2 expression with breast cancer subtypes and their use as potential biomarkers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304396

23 August 2017

Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304396

23 August 2017

Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Co

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304396

23 August 2017

Matricellular proteins: priming the tumour microenvironment for cancer development and metastasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304396

23 August 2017

Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304396

23 August 2017

Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304396

23 August 2017

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304396

23 August 2017

Use of archived specimens in evaluation of prognostic and predictive biomarkers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304396

23 August 2017

Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304396

23 August 2017

Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304396

23 August 2017

Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304396

23 August 2017

Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304396

23 August 2017

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304396

23 August 2017

The role of osteopontin in breast cancer: clinical and experimental studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304396

23 August 2017

The functional and clinical roles of osteopontin in cancer and metastasis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304396

23 August 2017

Tissue microarrays: a powerful tool for high-throughput analysis of clinical specimens: a review of the method with validation data.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304396

23 August 2017

Expression of osteopontin and osteonectin in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304396

23 August 2017

Tissue microarrays for high-throughput molecular profiling of tumor specimens

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304396

23 August 2017

Tumor-derived osteopontin reprograms normal mammary fibroblasts to promote inflammation and tumor growth in breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304396

6 September 2017

Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304396

6 September 2017

Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304396

6 September 2017

Osteopontin expression profiles predict pathological and clinical outcome in breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304396

14 September 2017

The role of osteopontin expression in melanoma progression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304396

28 September 2017

Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304396

28 September 2017

Association of increased osteopontin and splice variant-c mRNA expression with HER2 and triple-negative/basal-like breast carcinomas subtypes and recurrence.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304396

25 June 2018

Osteopontin expression according to molecular profile of invasive breast cancer: a clinicopathological and immunohistochemical study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304396

25 June 2018

Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304396

1 September 2018

Increased expression of osteopontin in patients with triple-negative breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304396

1 September 2018

REporting recommendations for tumor MARKer prognostic studies (REMARK).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304396

1 September 2018

Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304396

1 September 2018

Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304396

1 September 2018

Differential modulation of transcriptional activity of estrogen receptors by direct protein-protein interactions with the T cell factor family of transcription factors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304396

1 September 2018

Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial

1 reference

https://api.crossref.org/works/10.1186%2FS12967-017-1134-7

21 January 2018

Osteopontin expression in a group of lymph node negative breast cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/28193231

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A Hellenic Cooperative Oncology Group (HeCOG) Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/28193231

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/28193231

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic values of osteopontin-c, E-cadherin and β-catenin in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/28193231

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association of S100A4 and osteopontin with specific prognostic factors and survival of patients with minimally invasive breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/28193231

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Osteopontin C mRNA expression is associated with a poor clinical outcome in human breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/28193231

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system

1 reference

https://pubmed.ncbi.nlm.nih.gov/28193231

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation

1 reference

https://pubmed.ncbi.nlm.nih.gov/28193231

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/S12967-017-1134-7

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Dimensions Publication ID

0 references

release_xb4klzgi2bbl3pxbfmlcwf72pe

1 reference

https://api.fatcat.wiki/v0/release/xb4klzgi2bbl3pxbfmlcwf72pe

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37638287&oldid=2247517997"